Killed but metabolically active bacillus anthracis vaccines induce broad and protective immunity against anthrax

Infection and Immunity

Volumn 77, Issue 4, 2009, Pages 1649-1663

  Skoble, Justin ^a,g   Beaber, John W ^b,f   Yi, Gao ^c   Lovchik, Julie A ^d   Sower, Laurie E ^e   Liu, Weiqun ^a   Luckett, William ^a   Peterson, Johnny W ^e   Calendar, Richard ^b   Portnoy, Daniel A ^b   Lyons, Rick C ^d   Dubensky Jr , Thomas W ^a  

^a Anza Therapeutics Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CERUS CORPORATION   (United States)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

^f Xoma LLC   (United States)

^g 2423 Roosevelt Avenue ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; PSORALEN; TOXIN; TOXIN ANTIBODY; PSORALEN DERIVATIVE; S 59, PSORALEN; S-59, PSORALEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBODY PRODUCTION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG POTENCY; DRUG TOLERABILITY; EXCISION REPAIR; FEMALE; GENE DELETION; GUINEA PIG; IMMUNITY; INJECTION SITE INFLAMMATION; LETHAL DOSE; LETHAL GENE; MOUSE; NONHUMAN; PHOTOCHEMISTRY; POINT MUTATION; PRIORITY JOURNAL; PROVOCATION TEST; RABBIT; TOXIN SYNTHESIS; ULTRAVIOLET RADIATION; VACCINATION; ANIMAL; BACTERIAL SPORE; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DBA MOUSE; GENETICS; IMMUNOLOGY; MICROBIOLOGY; MUTATION; PATHOGENICITY; RADIATION EXPOSURE; VIRULENCE;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; FEMALE; GUINEA PIGS; IMMUNITY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MUTATION; PSORALENS; RABBITS; SPORES, BACTERIAL; ULTRAVIOLET RAYS; VACCINATION; VACCINES, INACTIVATED; VIRULENCE;

EID: 63149158639     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00530-08     Document Type: Article

References (66)

1. Agrawal, A., J. Lingappa, S. H. Leppla, S. Agrawal, A. Jabbar, C. Quinn, and B. Pulendran. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424:329-334.
2. +-T-cell potency during bacterial infection. Infect. Immun. 74:6387-6397.
3. Baldari, C. T., F. Tonello, S. R. Paccani, and C. Montecucco. 2006. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. 27:434-440.
4. Banks, D. J., S. C. Ward, and K. A. Bradley. 2006. New insights into the functions of anthrax toxin. Exp. Rev. Mol. Med. 8:1-18.
5. Barak, I., and P. Youngman. 1996. SpoIIE mutants of Bacillus subtilis com-prise two distinct phenotypic classes consistent with a dual functional role for the SpoIIE protein. J. Bacteriol. 178:498-4989.
6. Bourgogne, A., M. Drysdale, S. G. Hilsenbeck, S. N. Peterson, and T. M. Koehler. 2003. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect. Immun. 71:2736-2743.
7. Brockstedt, D. G., K. S. Bahjat, M. A. Giedlin, W. Liu, M. Leong, W. Luckett, Y. Gao, P. Schnupf, D. Kapadia, G. Castro, J. Y. Lim, A. Sampson-Johannes, A. A. Herskovits, A. Stassinopoulos, H. G. Bouwer, J. E. Hearst, D. A. Portnoy, D. N. Cook, and T. W. Dubensky, Jr. 2005. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat. Med. 11:853-860.
8. Brockstedt, D. G., M. A. Giedlin, M. L. Leong, K. S. Bahjat, Y. Gao, W. Luckett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky, Jr. 200 Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101:13832-13837.
9. Brossier, F., M. Levy, and M. Mock. 2002. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70:661-664.
10. Brossier, F., M. Weber-Levy, M. Mock, and J. C. Sirard. 2000. Role of toxin functional domains in anthrax pathogenesis. Infect. Immun. 68:1781-1786.
11. Camilli, A., L. G. Tilney, and D. A. Portnoy. 1993. Dual roles of plcA in Listeria monocytogenes pathogenesis. Mol. Microbiol. 8:143-157.
12. Cataldi, A., E. Labruyere, and M. Mock. 1990. Construction and characterization of a protective antigen-deficient Bacillus anthracis strain. Mol. Mi-crobiol. 4:1111-1117.
13. Chabot, D. J., A. Scorpio, S. A. Tobery, S. F. Little, S. L. Norris, and A. M. Friedlander. 2004. Anthrax capsule vaccine protects against experimental infection. Vaccine 23:43-17.
14. Crawford, M. A., C. V. Aylott, R. W. Bourdeau, and G. M. Bokoch. 2006. Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J. Immunol. 176:7557-7565.
15. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
16. Fang, H., L. Xu, T. Y. Chen, J. M. Cyr, and D. M. Frucht. 2006. Anthrax lethaltoxinhas directandpotentinhibitoryeffectsonBcellproliferationand immunoglobulin production. J. Immunol. 176:6155-6161.
17. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
18. Glomski, I. J., J. P. Corre, M. Mock, and P. L. Goossens. 2007. Cuttingedge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J. Immunol. 178:2646-2650.
19. Gorse, G. J., W. Keitel, H. Keyserling, D. N. Taylor, M. Lock, K. Alves, J. Kenner, L. Deans, and M. Gurwith. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24:5950-5959.
20. Green, B. D., L. Battisti, T. M. Koehler, C. B. Thorne, and B. E. Ivins. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49:291-297.
21. Harvill, E. T., G. Lee, V. K. Grippe, and T. J. Merkel. 2005. Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain. Infect. Immun. 73:4420-4422.
22. Heninger, S., M. Drysdale, J. Lovchik, J. Hutt, M. F. Lipscomb, T. M. Koehler, and C. R. Lyons. 2006. Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect. Immun. 74:6067-6074.
23. Hering, D., W. Thompson, J. Hewetson, S. Little, S. Norris, and J. Pace- Templeton. 2004. Validation of the anthrax lethal toxin neutralization assay. Biologicals 32:17-27.
24. Horton, R. M., Z. L. Cai, S. N. Ho, and L. R. Pease. 1990. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8:528-535.
25. Huang, J., J. A. Mikszta, M. S. Ferriter, G. Jiang, N. G. Harvey, B. Dyas, C. J. Roy, R. G. Ulrich, and V. J. Sullivan. 2007. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum. Vaccin. 3:90-93.
26. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
27. Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthraxtoxinlethalfactor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100.
28. Kozel, T. R., W. J. Murphy, S. Brandt, B. R. Blazar, J. A. Lovchik, P. Thorkildson, A. Percival, and C. R. Lyons. 2004. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigen-emia. Proc. Natl. Acad. Sci. USA 101:5042-5047.
29. Labruyere, E., M. Mock, W. K. Surewicz, H. H. Mantsch, T. Rose, H. Munier, R. S. Sarfati, and O. Barzu. 1991. Structural and ligand-binding properties of a truncated form of Bacillus anthracis adenylate cyclase and of a catalytically inactive variant in which glutamine substitutes for lysine-346. Biochemistry 30:2619-2624.
30. Lankowski, A. J., and E. L. Hohmann. 2007. Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector. J. Infect. Dis. 195:1203-1211.
31. Leppla,S.H.1982.Anthraxtoxinedemafactor: abacterialadenylatecyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166.
32. Leverone, M. R., T. C. Owen, F. S. Tieder, G. J. Stewart, and D. V. Lim. 1996. Resting-cell dehydrogenase assay measuring a novel water-soluble formazan detects catabolic differences among cells. J. Microbiol. Methods 25:49-55.
33. Lin, L., D. N. Cook, G. P. Wiesehahn, R. Alfonso, B. Behrman, G. D. Cimino, L. Corten, P. B. Damonte, R. Dikeman, K. Dupuis, Y. M. Fang, C. V. Hanson, J. E. Hearst, C. Y. Lin, H. F. Londe, K. Metchette, A. T. Nerio, J. T. Pu, A. A. Reames, M. Rheinschmidt, J. Tessman, S. T. Isaacs, S. Wollowitz, and L. Corash. 1997. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37:423-435.
34. Little, S. F., B. E. Ivins, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430.
35. Little, S. F., B. E. Ivins, W. M. Webster, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2006. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24:2530-2536.
36. Little, S. F., and G. B. Knudson. 1986. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 52:509-512.
37. Makino, S., I. Uchida, N. Terakado, C. Sasakawa, and M. Yoshikawa. 1989. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J. Bacteriol. 171:722-730.
38. McNeil, M. M., I. S. Chiang, J. T. Wheeling, and Y. Zhang. 2007. Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature. Pharmacoepidemiol. Drug Saf. 16:259-274.
39. Mock, M., E. Labruyere, P. Glaser, A. Danchin, and A. Ullmann. 1988. Cloning and expression of the calmodulin-sensitive Bacillus anthracis ade- nylate cyclase in Escherichia coli. Gene 64:277-284.
40. Paccani, S. R., F. Tonello, R. Ghittoni, M. Natale, L. Muraro, M. M. D'Elios, W. J. Tang, C. Montecucco, and C. T. Baldari. 2005. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 201:325-331.
41. Peterson, J. W., J. E. Comer, W. B. Baze, D. M. Noffsinger, A. Wenglikowski, K. G. Walberg, J. Hardcastle, J. Pawlik, K. Bush, J. Taormina, S. Moen, J. Thomas, B. M. Chatuev, L. Sower, A. K. Chopra, L. R. Stanberry, R. Sawada, W. W. Scholz, and J. Sircar. 2007. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus an- thracis Ames strain from the lungs in a rabbit model. Infect. Immun. 75:3414-3424.
42. Phipps, A. J., C. Premanandan, R. E. Barnewall, and M. D. Lairmore. 2004. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol. Mol. Biol. Rev. 68:617-629.
43. Pitt, M. L., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
44. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493.
45. Rhie, G. E., M. H. Roehrl, M. Mourez, R. J. Collier, J. J. Mekalanos, and J. Y. Wang. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. USA 100:10925-10930.
46. Ristroph, J. D., and B. E. Ivins. 1983. Elaboration of Bacillus anthracis antigens in a new, defined culture medium. Infect. Immun. 39:483-486.
47. Robertson, D. L., and S. H. Leppla. 1986. Molecular cloning and expression in Escherichia coli of the lethal factor gene of Bacillus anthracis. Gene 44:71-78.
48. Rossi Paccani, S., F. Tonello, L. Patrussi, N. Capitani, M. Simonato, C. Montecucco, and C. T. Baldari. 2007. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell Microbiol. 9:924-929.
49. Sancar, A., and G. B. Sancar. 1988. DNA repair enzymes. Annu. Rev. Biochem. 57:29-67.
50. Sever, J. L., A. I. Brenner, A. D. Gale, J. M. Lyle, L. H. Moulton, B. J. Ward, and D. J. West. 2004. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol. Drug Saf. 13:825-840.
51. Shlyakhov, E. N., and E. Rubinstein. 1994. Human live anthrax vaccine in the former USSR. Vaccine 12:727-730.
52. Sterne, M. 1939. The use of anthrax vaccines prepared from avirulent (un- capsulated) varients of Bacillus anthracis. Onderstepoort J. Vet. Sci. Anim. Ind. 13:307-312.
53. Tippetts, M. T., and D. L. Robertson. 1988. Molecular cloning and expres-sion of the Bacillus anthracis edema factor toxin gene: a calmodulin-depen- dent adenylate cyclase. J. Bacteriol. 170:2263-2266.
54. Tournier, J. N., A. Quesnel-Hellmann, J. Mathieu, C. Montecucco, W. J. Tang, M. Mock, D. R. Vidal, and P. L. Goossens. 2005. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 174:4934-4941.
55. Trull, M. C., T. V. du Laney, and M. D. Dibner. 2007. Turning biodefense dollars into products. Nat. Biotechnol. 25:179-184.
56. Turnbull, P. C. 1991. Anthrax vaccines: past, present and future. Vaccine 9:533-539.
57. Uchida, I., K. Hashimoto, and N. Terakado. 1986. Virulence and immuno- genicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids. J. Gen. Microbiol. 132:557-559.
58. Vodkin, M. H., and S. H. Leppla. 1983. Cloning of the protective antigen gene of Bacillus anthracis. Cell 34:693-697.
59. -) Bacillus anthracis. Microb. Pathog. 10:183-198.
60. Welkos, S. L., and A. M. Friedlander. 1988. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 4:53-69.
61. Welkos, S. L., T. J. Keener, and P. H. Gibbs. 1986. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 51:795-800.
62. Welkos, S. L., N. J. Vietri, and P. H. Gibbs. 1993. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb. Pathog. 14:381-388.
63. Wimer-Mackin, S., M. Hinchcliffe, C. R. Petrie, S. J. Warwood, W. T. Tino, M. S. Williams, J. P. Stenz, A. Cheff, and C. Richardson. 2006. Anintranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 24:3953-3963.
64. Wollowitz, S. 2001. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin. Hematol. 38:4-11.
65. Xia, Z. G., and D. R. Storm. 1990. A-type ATP binding consensus sequences are critical for the catalytic activity of the calmodulin-sensitive adenylyl cyclase from Bacillus anthracis. J. Biol. Chem. 265:6517-6520.
66. Zaucha, G. M., L. M. Pitt, J. Estep, B. E. Ivins, and A. M. Friedlander. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992.